Shield Therapeutics plc (LON:STX – Get Free Report) rose 10.1% during mid-day trading on Thursday . The stock traded as high as GBX 5.53 and last traded at GBX 5.45. 2,546,040 shares traded hands during trading, an increase of 13% from the average session volume of 2,251,328 shares. The stock had previously closed at GBX 4.95.
Shield Therapeutics Trading Up 10.9%
The stock has a market capitalization of £65.24 million, a P/E ratio of -3.05 and a beta of 1.72. The company has a current ratio of 0.75, a quick ratio of 2.16 and a debt-to-equity ratio of -146.28. The company has a 50-day moving average price of GBX 5.40 and a 200 day moving average price of GBX 7.13.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Further Reading
- Five stocks we like better than Shield Therapeutics
- Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
- MarketBeat Week in Review – 08/24 – 08/28
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
